Myovant Sciences to Present at Upcoming Investor Conferences
February 22 2021 - 8:30AM
Myovant Sciences (NYSE: MYOV), a healthcare company focused on
redefining care for women and for men, invites investors and the
general public to listen to webcasts at the following investor
conferences:
- SVB Leerink 10th
Annual Global Healthcare Conference on February
25, 2021 at 3:40 p.m. Eastern Time. David Marek, Chief Executive
Officer of Myovant Sciences, Inc., and Frank Karbe, President and
Chief Financial Officer of Myovant Sciences, Inc., will participate
in a fireside chat. Management will also participate in one-on-one
investor meetings on February 25.
- Cowen 41st Annual
Health Care Conference on March 2, 2021 at 11:10 a.m.
Eastern Time. Mr. Marek and Mr. Karbe will participate in a
fireside chat. Management will also participate in one-on-one
investor meetings on March 2.
The presentations will be accessible on the Events page under
the Investors & Media section of the Myovant website at
www.myovant.com.
About Myovant Sciences Myovant
Sciences aspires to redefine care for women and for men
through purpose-driven science, empowering medicines, and
transformative advocacy. We have one FDA-approved medicine,
ORGOVYX™ (relugolix), for adult patients with advanced
prostate cancer. Our lead product candidate, relugolix combination
tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone
acetate 0.5 mg), is under regulatory review in Europe and
the U.S. for women with uterine fibroids and is under
development for women with endometriosis. We are also developing
MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has
completed a Phase 2a study for female infertility as part of
assisted reproduction. Sumitovant Biopharma, Ltd., a wholly
owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our
majority shareholder. For more information, please visit our
website at www.myovant.com. Follow @Myovant on
Twitter and LinkedIn.
Investor Contact:Ryan CroweVice President,
Investor Relations Myovant Sciences, Inc.+1 (650)
781-9106investors@myovant.com
Media Contact:Albert Liao Director,
Corporate CommunicationsMyovant Sciences, Inc.+1 (650)
410-3055media@myovant.com
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Sep 2023 to Sep 2024